80 related articles for article (PubMed ID: 30535744)
1. Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):533-534. PubMed ID: 30535744
[TBL] [Abstract][Full Text] [Related]
2. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):421-428. PubMed ID: 30218317
[TBL] [Abstract][Full Text] [Related]
3. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
Lasnon C; Salomon T; Desmonts C; Dô P; Oulkhouir Y; Madelaine J; Aide N
Ann Nucl Med; 2017 Feb; 31(2):125-134. PubMed ID: 27812791
[TBL] [Abstract][Full Text] [Related]
4.
Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
[TBL] [Abstract][Full Text] [Related]
5. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs).
Lasnon C; Enilorac B; Popotte H; Aide N
EJNMMI Res; 2017 Dec; 7(1):30. PubMed ID: 28361349
[TBL] [Abstract][Full Text] [Related]
6. SUV Harmonization Between Different Hybrid PET/CT Systems.
Rubello D; Colletti PM
Clin Nucl Med; 2018 Nov; 43(11):811-814. PubMed ID: 30199381
[TBL] [Abstract][Full Text] [Related]
7. EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.
Kaalep A; Sera T; Oyen W; Krause BJ; Chiti A; Liu Y; Boellaard R
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):412-422. PubMed ID: 29192365
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F-FDG PET/CT for Salivary Gland Carcinoma With High-Risk Histology.
Cheng NM; Hsieh CE; Liao CT; Ng SH; Wang HM; Fang YD; Chou WC; Lin CY; Yen TC
Clin Nucl Med; 2019 May; 44(5):351-358. PubMed ID: 30932974
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
[TBL] [Abstract][Full Text] [Related]
14. Test-Retest Variability in Lesion SUV and Lesion SUR in
Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
[TBL] [Abstract][Full Text] [Related]
15. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
16. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.
Quak E; Le Roux PY; Hofman MS; Robin P; Bourhis D; Callahan J; Binns D; Desmonts C; Salaun PY; Hicks RJ; Aide N
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2072-82. PubMed ID: 26219870
[TBL] [Abstract][Full Text] [Related]
17. Comparison of SUVmax and SUVpeak based segmentation to determine primary lung tumour volume on FDG PET-CT correlated with pathology data.
Mercieca S; Belderbos J; van Loon J; Gilhuijs K; Julyan P; van Herk M
Radiother Oncol; 2018 Nov; 129(2):227-233. PubMed ID: 29983260
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
19. A new method for segmentation of FDG PET metabolic tumour volume using the peritumoural halo layer and a 10-step colour scale. A study in patients with papillary thyroid carcinoma.
Jun S; Kim H; Nam HY
Nuklearmedizin; 2015; 54(6):272-85. PubMed ID: 26429587
[TBL] [Abstract][Full Text] [Related]
20. Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET.
Akamatsu G; Mitsumoto K; Taniguchi T; Tsutsui Y; Baba S; Sasaki M
Eur J Radiol; 2014 Jan; 83(1):226-30. PubMed ID: 24144448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
